Canopy Partners LLC Buys 2,024 Shares of Pfizer Inc. $PFE

Canopy Partners LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 5.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,618 shares of the biopharmaceutical company’s stock after buying an additional 2,024 shares during the period. Canopy Partners LLC’s holdings in Pfizer were worth $888,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the first quarter worth about $27,000. North Capital Inc. acquired a new position in Pfizer in the first quarter worth about $28,000. Bayforest Capital Ltd acquired a new position in Pfizer in the first quarter worth about $28,000. Horizon Financial Services LLC acquired a new position in Pfizer in the first quarter worth about $35,000. Finally, WPG Advisers LLC acquired a new position in Pfizer in the first quarter worth about $35,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley increased their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.41.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.27 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market cap of $149.36 billion, a P/E ratio of 13.97, a P/E/G ratio of 0.86 and a beta of 0.55. The firm has a 50 day simple moving average of $24.76 and a 200 day simple moving average of $24.14. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.